



(11)

EP 3 261 658 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

**Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73**

(51) Int Cl.:

A61K 38/12 (2006.01) A61P 31/00 (2006.01)

(86) International application number:

PCT/US2016/018396

(48) Corrigendum issued on:

05.06.2019 Bulletin 2019/23

(87) International publication number:

WO 2016/137806 (01.09.2016 Gazette 2016/35)

(45) Date of publication and mention
of the grant of the patent:

03.04.2019 Bulletin 2019/14

(21) Application number: **16708853.3**

(22) Date of filing: **18.02.2016**

(54) DOSES AND METHODS OF ADMINISTERING TELAVANCIN

DOSEN UND VERFAHREN ZUR VERABREICHUNG VON TELAVANCIN

DOSES ET PROCÉDÉS D'ADMINISTRATION DE TÉLAVANCINE

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

Designated Extension States:

BA ME

(74) Representative: **Bassil, Nicholas Charles**

Kilburn & Strode LLP

Lacon London

84 Theobalds Road

London WC1X 8NL (GB)

(30) Priority: **23.02.2015 US 201562119592 P**

(56) References cited:

WO-A2-2005/042568

(43) Date of publication of application:

03.01.2018 Bulletin 2018/01

(73) Proprietor: **Cumberland Pharmaceuticals Inc.**

Nashville, TN 37203 (US)

- **G. R. COREY ET AL: "Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 58, no. 4, 1 April 2014 (2014-04-01), pages 2030-2037, XP055271375, US ISSN: 0066-4804, DOI: 10.1128/AAC.02330-13**
- **T. P. LODISE ET AL: "Telavancin Pharmacokinetics and Pharmacodynamics in Patients with Complicated Skin and Skin Structure Infections and Various Degrees of Renal Function", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 56, no. 4, 1 April 2012 (2012-04-01), pages 2062-2066, XP055271388, US ISSN: 0066-4804, DOI: 10.1128/AAC.00383-11**

(72) Inventors:

- **BARRIERE, Steven L.
San Francisco, California 94115 (US)**
- **LO, Arthur
San Francisco, California 94122 (US)**
- **MAMMEN, Mathai
Menlo Park, California 94025 (US)**
- **WORBOYS, Philip
San Mateo, California 94402 (US)**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 261 658 B8

- **ETHAN RUBINSTEIN ET AL:** "Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia", **EXPERT OPINION ON PHARMACOTHERAPY**, vol. 12, no. 17, 15 December 2011 (2011-12-15), pages 2737-2750, XP055271400, LONDON, UK ISSN: 1465-6566, DOI: 10.1517/14656566.2011.633511
- **M. P. PAI:** "Comment on: Acute renal insufficiency during telavancin therapy in clinical practice", **JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY.**, vol. 67, no. 5, 13 February 2012 (2012-02-13), pages 1300-1301, XP055271518, GB ISSN: 0305-7453, DOI: 10.1093/jac/dks029
- **SAMUEL ERIC WILSON ET AL:** "Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections", **INFECTION AND DRUG RESISTANCE**, 1 March 2011 (2011-03-01), page 87, XP055293510, DOI: 10.2147/IDR.S5327